The present study was conducted to evaluate gene expression profile of c-erbB-3 and bcl2 in hepatocellular carcinoma patients (HCC) 
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common causes of death from cancer in several regions in the world including Egypt. In spite of enormous efforts to improve clinical treatment, HCC remains a major carcinoma with high mortality. Poor differentiation, larger size, portal invasion and intra-hepatic metastasis are known to shorten disease free survival with that carcinoma. One of the most prominent parameters in evaluation of the biological aggressiveness of carcinoma is the investigation of cell behavior. Growth factor receptors with tyrosine kinase activity are known to contribute greatly to the regulation of cell behavior such as cell growth, proliferation and mortality [1, 2] . The type I family of growth factor receptors is the most prominent and is recognized as a proto-oncogene family. The family includes the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases that includes cell erythroblastic leukemia viral oncogene homolog 3 (c-erbB-3) [3, 4] . When specific ligands bind to a receptor of the family, the receptor is activated by phosphorylation of the tyrosine residue in the molecule [1] . It then forms a dimer with another receptor of that family, causing activation by transphosphorylation which contributes to a variety of growth signal transductions [5] . These receptors share high sequence identity with each other and are coexpressed in various combinations in neoplasms. Thus far, of the four receptors of the family, the expression of c-erbB-3 has been investigated in various neoplasms, including malignancies of the liver and biliary tract . On the other hand, The B-cell lymphoma 2 (bcl-2) gene family is a group of apoptosis-related genes which are studied extensively at present [14] . Accumulated reports show that there is a high-level expression of bcl-2 in many tumor tissues [15, 16] . Primary HCC is a very common malignant tumor in Egypt [17] . Yildiz et al. [17] ,also, stated that bcl-2 is highly expressed in B and C hepatitis and hepatocellular carcinomas. The high incidence of bcl-2 activity in the nonneoplastic liver parenchyma of the HCC cases suggest that bcl-2 activation may be involved in the development of at least some cases of hepatocellular carcinoma.
The present study was conducted to evaluate gene expression profile cerbB-3 and bcl2 of in hepatocellular carcinoma patients (HCC) with and without HCV associated infection. Correlations with various clinicpathological parameters of the tumor were assessed to find whether the expression profile of the studied genes could be used as prognostic markers in hepatocellular carcinoma patients.
MATERIAL & METHODS

Tissue specimens
10% buffered formalin-fixed paraffin-embedded blocks of HCC were prepared from 48 patients who had undergone surgery for HCC in Kasr -elaini hospital pathology archeive -Faculty of Medicine, Cairo University. Informed consent was obtained from each patient. The clinico-pathological characteristics of the patients were shown in Table 1 .
Gene expression profile of c-erb-B3 and bcl2 in HCC samples [18, 19] , Total RNA was extracted using the easy ribonucleic acid (RNeasy) Purification Reagent (Promega, Madison, WI, USA), and then a sample (1 µg) was reverse transcribed with Moleny-Murine Leukemia virus (M-MLV) reverse transcriptase (RT) for 30 min at 42°C in the presence of oligo deoxynucleotides (oligo-dT) primer. Polymerase chain reaction (PCR) was performed using primers specified on Table 2 . PCR was performed for 45 cycles, with each cycle consisting of denaturation at 95°C for 30 seconds, annealing at 58.5°C to 59.5°C as specified for each primer pairs for 30 sec and elongation at 72°C for 1 min, with an additional 10-min incubation at 72°C after completion of the last cycle. To exclude the possibility of contaminating genomic DNA, PCRs were also run without RT. Beta actin gene expression was assessed as a positive control housekeeping gene. The PCR product was separated by electrophoresis through a 1% agarose gel, stained, and photographed under ultraviolet light.
Semiquantification of PCR products by Gel documentation
RT-PCR of the gene products was semiquantified using densitometry gel documentation system (BioDocAnalyze, Biometra, Goettingen, Germany) according to the manufacturer , s specifications of the software. The amounts of PCR products were evaluated according to the relative intensity of the studied genes and beta actin bands by using the computed densitometry assay of the Biometra BioDoc Analyze System.
Statistical analyses
Values were expressed in (Fig.4 ) The chi-squared test and KruskalWallis test followed by Dunn's test of multiple comparisons were employed for analyses of the relationship between the expression of the genes and various clinicopathological parameters. p value less than 0.05 was considered to be statistically significant. All of the statistical analyses were performed using statistical package for social studies (SPSS) version 10 software (SPSS,Chicago, IL).
RESULTS
In the present study, c-erbB-3 oncogene was highly expressed all HCC samples as compared to the adjacent paracancerous lesions (Fig.1 ) whereas bcl-2 gene showed equal expression in HCC samples as compared to paracancerous tissues (Fig. 2) . Beta actin gene was expressed in all samples (Fig. 3) .
Moreover, c-erbB3 was overexpressed in of HCC samples with HCV associated infection as compared to HCC without HCV associated infection (Fig. 4) whereas bcl-2 genes were equally expressed in HCC samples with or without HCV associated infection (Fig. 5) .
Furthermore, gene expression of c-erbB-3 showed significant positive correlation to the clinic-pathological parameters of the tumor, whereas, gene expression of bcl2 did not show any significant correlations to the clinico-pathological parameters of the tumor (Table 3 ). 
DISCUSSION
In the present study, c-erbB-3 oncogene was highly expressed all HCC samples as compared to the adjacent para-cancerous lesions. Moreover, c-erbB3 was overexpressed in cases of HCC samples with HCV associated infection as compared to HCC without HCV associated infection. Gene expression of c-erbB-3 was significantly correlated to the clinic-pathological parameters of the tumor. Similar studies have been performed on a few other carcinomas. For example, Sanidas et al., [20] demonstrated that the c-erbB-3 protein was always expressed in both gastric carcinoma and the adjacent mucosa, but the expression level was usually higher in the carcinoma. Travis et al., [21] observed that breast carcinoma expressed c-erbB-3 more intensely and diffusely than the adjacent normal glands which were usually weakly or moderately positive for that protein.
Haugen et al. [22] showed that normal follicles of the thyroid were all negative for c-erbB-3, whereas all types of thyroid carcinoma expressed that protein with very high incidence. The results of these studies including ours are similar in that they show cerbB-3 expression to be more diffuse and/or more intense in the carcinoma nest than in normal or benign lesions [23, 24] . Our study also showed that c-erbB-3 expression in HCC was significantly related to some important markers of carcinoma progression, which are also predictors of recurrence, such as stage, tumor size, intrahepatic metastasis and carcinoma differentiation. Furthermore, c-erbB-3 itself, to some extent, affects diseasefree survival as reported in several studies [25] [26] [27] . To our knowledge there is no previous study conducted to evaluate the role of c-erb-B3 in liver tissue with hepatitis C virus nor in HCV associated HCC. However, El Bassuoni et al. [28] reported that the elevated expression of another member of the c-erbB family of oncogenes (C-erbB-2) in HCV related chronic liver disease may reflect preneoplastic liver cell proliferation, cellular necrosis associated with chronic liver disease or HCV carcinogens which enhance malignant transformation.
As regards bcl2 gene expression, the gene was expressed to an equal extent in all HCC samples and in all para-cancerous lesions. Bcl2 was equally expressed in HCC samples with and without associated HCV infection. Gene expression of bcl2 did not show significant positive correlation to the clinic-pathological parameters of the tumor Also, Yang et al. [29] stated that the expression of Bcl-2 protein in most tumor tissues is stronger than that in the tissues of origin. Nevertheless, most studies have demonstrated that HCC tissues do not express or have only a low positive rate of Bcl-2 protein. Moreover, sometimes the positive rate of Bcl-2 in HCC tissues was lower than that in the non-tumor liver tissues immediately adjacent to HCC tissues ,the mechanism of that phenomenon is still unclear. There may be specific characteristics of the regulation of Bcl-2 in HCC. As regards HCC samples with hepatitis C virus, results of the present study coincided with the study of Tsamandas et al.
[31] who found bcl2 expression in liver biopsies with hepatitis B or C viruses. Moreover, Yildiz et al. [17] studied Bcl-2 gene expression in B and C hepatitis and hepatocellular carcinomas. The authors stated that no causative relation between bcl-2 positivity and hepatocellular carcinoma could be implied, however the high incidence of bcl-2 activity in the non-neoplastic liver parenchyma of the HCC cases suggests that bcl-2 activation may be involved in the development of at least some cases of hepatocellular carcinoma. Case control and/or prospective studies are needed to show whether bcl-2 positivity in a chronic hepatitis case has a predictive value for the development of hepatocellular carcinoma.
In conclusion, c-erbB-3 gene was over-expressed in HCC samples whereas, c-erbB-3 gene showed significant correlations to the clinicopathological parameters of the subjects, whereas, bcl2 did not show any correlation to the clinicopathological parameters. Gene expression profile of c-erb-B3 could be used as a prognostic molecular marker in HCC.
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